Dublin, Nov. 06, 2017 -- The "Vaccine Adjuvants Market Size And Forecast By Type, By Application, And Trend Analysis, 2014 - 2025" report has been added to Research and Markets' offering.
The global vaccine adjuvants market is expected to reach USD 758.8 million by 2025
The significance of adjuvant research in the development of vaccines has increased gradually due to inadequate immunogenicity of innovative vaccine antigens. In addition, the growing focus on long-lasting immunization effect against existing and emerging diseases is expected to boost the demand for vaccine adjuvants.
Furthermore, rising prevalence of cervical cancer is anticipated to boost the market. According to NCBI, around 15,000 females die every year due to cervical cancer. There are certain companies developing vaccine adjuvants for this type of cancer in order to enhance the efficacy, such as AS04 adjuvant-adsorbed (human papillomavirus vaccine) by GSK, which boosts the immune response for a longer duration.
Further key findings from the report suggest:
- Particulate product type dominated the market in 2016 due to greater efficiency of vaccines, presence of wide range of products, easier availability, and improved safety
- Pathogen is anticipated to be the fastest growing segment with a CAGR of 11.9% due to the availability of naturally occurring pathogens used as adjuvants
- Among the route of administration, intramuscular held the largest market share in 2016 due to the high immune specificity of vaccines
- Infectious disease segment dominated the market in 2016 by application, due to the increasing prevalence of infectious diseases such as hepatitis A, B, C, influenza, meningitis, and others
- Cancer is expected to be the fastest growing application segment because of the rising prevalence of cancer and growing R&D activities to treat various types of cancer
- Asia Pacific is estimated to be the fastest growing region over the forecast period with a significant CAGR from 2017 to 2025 due to the presence of huge target population and rise in disposable income
Key Topics Covered:
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Vaccine Adjuvants Market Variables, Trends, & Scope
Chapter 4 Vaccine Adjuvants Market: Type Estimates & Trend Analysis
Chapter 5 Vaccine Adjuvants Market: Application Estimates & Trend Analysis
Chapter 6 Vaccine Adjuvants Market: Administration Estimates & Trend Analysis
Chapter 7 Vaccine Adjuvants Market: Regional Estimates & Trend Analysis, By Administration, Type & Application
Chapter 8 Competitive Landscape
- GSK
- Novartis/CSL
- Agenus
- Adjuvance
- Novavax
- SPI Pharma
- Invivogen
- Avanti Polar Lipids
- Brentagg
For more information about this report visit https://www.researchandmarkets.com/research/3qftxk/vaccine_adjuvants
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Vaccines


Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings
Lockheed Martin Secures $101M in U.S. Defense Contracts for AEGIS, F-35, and Missile Systems
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase
Anduril Eyes $60 Billion Valuation in New Funding Round to Expand Defense Manufacturing and Autonomous Fighter Jet Development
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions
Paramount Skydance Appoints Rene Augustine as SVP of Global Public Policy Amid Warner Bros Takeover Battle
Sachem Head Boosts Warner Bros. Discovery Stake Amid Netflix Deal and Paramount Bid
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 



